Compounds > nesosteine
Page last updated: 2024-11-07

nesosteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID158613
CHEMBL ID2107446
SCHEMBL ID1525263
MeSH IDM0141924

Synonyms (19)

Synonym
nesosoteinum
2-(1,3-thiazolidine-3-carbonyl)benzoic acid
unii-445j9k442z
nesosteine
nesosteinum [latin]
nesosteine [inn]
nesosteina
84233-61-4
2-(3-thiazolidinylcarbonyl)benzoesaeure
445j9k442z ,
nesosteinum
o-(3-thiazolidinylcarbonyl)benzoic acid
nesosteina [spanish]
CHEMBL2107446
nesosteine [mart.]
DTXSID60233155
SCHEMBL1525263
Q27258704
AKOS040753252

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The therapy was performed for 15 days, at the dosage of one vial given intramuscularly twice daily for the first seven days and then of one tablet orally thrice daily for the remaining eight days."( Clinical trial with CO-1177: a preliminary report.
Mbuyamba, P, 1986)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.96 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (37.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (62.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
tiopronin
Tiopronin: Sulfhydryl acylated derivative of GLYCINE.		1.9610N-acyl-amino acid
thiazoles
[no description available]		5.66731,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		1.9610acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
vinblastine
sobrerol: RN given is for parent cpd; structure		1.9610p-menthane monoterpenoid
ConditionIndicatedRelationship StrengthStudiesTrials
Anaphylactic Reaction
[description not available]		01.9710
Bronchospasm
[description not available]		01.9710
Anaphylaxis
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.		01.9710
Bronchial Spasm
Spasmodic contraction of the smooth muscle of the bronchi.		01.9710
Obstructive Lung Diseases
[description not available]		03.3611
Lung Diseases, Obstructive
Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.		03.3611
Bronchitis
Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.		04.3222